Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Italy Radioligand Therapy Market

ID: MRFR/Pharma/50335-HCR
200 Pages
Rahul Gotadki
Last Updated: March 28, 2026

Italy Radioligand Therapy RLT Market Research Report: Size, Share, Trend Analysis By Isotope (Fluorine – 18, Gallium – 68, Lutetium – 177, Others), By Targeted Receptor (Prostate-specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR), Epidermal Growth Factor Receptor (EGFR), Others), By Indication (Prostate Cancer, Neuroendocrine Tumors (NETs), Breast Cancer, Others) and By End Users (Hospitals & Clinics, Diagnostic Centers, Others) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Italy Radioligand Therapy Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Application (USD Billion)
  49.     4.1.1 Oncology
  50.     4.1.2 Cardiology
  51.     4.1.3 Neurology
  52.     4.1.4 Endocrinology
  53.   4.2 Healthcare, BY End Use (USD Billion)
  54.     4.2.1 Hospitals
  55.     4.2.2 Diagnostic Centers
  56.     4.2.3 Research Institutions
  57.     4.2.4 Pharmaceutical Companies
  58.   4.3 Healthcare, BY Type of Radioligand (USD Billion)
  59.     4.3.1 Alpha Emitters
  60.     4.3.2 Beta Emitters
  61.     4.3.3 Auger Emitters
  62.     4.3.4 Radionuclide
  63.   4.4 Healthcare, BY Administration Route (USD Billion)
  64.     4.4.1 Intravenous
  65.     4.4.2 Oral
  66.     4.4.3 Intratumoral
  67.   4.5 Healthcare, BY Target Disease (USD Billion)
  68.     4.5.1 Prostate Cancer
  69.     4.5.2 Neuroendocrine Tumors
  70.     4.5.3 Lung Cancer
  71.     4.5.4 Thyroid Cancer
  72. 5 SECTION V: COMPETITIVE ANALYSIS
  73.   5.1 Competitive Landscape
  74.     5.1.1 Overview
  75.     5.1.2 Competitive Analysis
  76.     5.1.3 Market share Analysis
  77.     5.1.4 Major Growth Strategy in the Healthcare
  78.     5.1.5 Competitive Benchmarking
  79.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  80.     5.1.7 Key developments and growth strategies
  81.       5.1.7.1 New Product Launch/Service Deployment
  82.       5.1.7.2 Merger & Acquisitions
  83.       5.1.7.3 Joint Ventures
  84.     5.1.8 Major Players Financial Matrix
  85.       5.1.8.1 Sales and Operating Income
  86.       5.1.8.2 Major Players R&D Expenditure. 2023
  87.   5.2 Company Profiles
  88.     5.2.1 Novartis (IT)
  89.       5.2.1.1 Financial Overview
  90.       5.2.1.2 Products Offered
  91.       5.2.1.3 Key Developments
  92.       5.2.1.4 SWOT Analysis
  93.       5.2.1.5 Key Strategies
  94.     5.2.2 Bayer (IT)
  95.       5.2.2.1 Financial Overview
  96.       5.2.2.2 Products Offered
  97.       5.2.2.3 Key Developments
  98.       5.2.2.4 SWOT Analysis
  99.       5.2.2.5 Key Strategies
  100.     5.2.3 Elekta (IT)
  101.       5.2.3.1 Financial Overview
  102.       5.2.3.2 Products Offered
  103.       5.2.3.3 Key Developments
  104.       5.2.3.4 SWOT Analysis
  105.       5.2.3.5 Key Strategies
  106.     5.2.4 Siemens Healthineers (IT)
  107.       5.2.4.1 Financial Overview
  108.       5.2.4.2 Products Offered
  109.       5.2.4.3 Key Developments
  110.       5.2.4.4 SWOT Analysis
  111.       5.2.4.5 Key Strategies
  112.     5.2.5 GE Healthcare (IT)
  113.       5.2.5.1 Financial Overview
  114.       5.2.5.2 Products Offered
  115.       5.2.5.3 Key Developments
  116.       5.2.5.4 SWOT Analysis
  117.       5.2.5.5 Key Strategies
  118.     5.2.6 Ipsen (IT)
  119.       5.2.6.1 Financial Overview
  120.       5.2.6.2 Products Offered
  121.       5.2.6.3 Key Developments
  122.       5.2.6.4 SWOT Analysis
  123.       5.2.6.5 Key Strategies
  124.     5.2.7 Lantheus Medical Imaging (IT)
  125.       5.2.7.1 Financial Overview
  126.       5.2.7.2 Products Offered
  127.       5.2.7.3 Key Developments
  128.       5.2.7.4 SWOT Analysis
  129.       5.2.7.5 Key Strategies
  130.     5.2.8 Point Biopharma (IT)
  131.       5.2.8.1 Financial Overview
  132.       5.2.8.2 Products Offered
  133.       5.2.8.3 Key Developments
  134.       5.2.8.4 SWOT Analysis
  135.       5.2.8.5 Key Strategies
  136.   5.3 Appendix
  137.     5.3.1 References
  138.     5.3.2 Related Reports
  139. 6 LIST OF FIGURES
  140.   6.1 MARKET SYNOPSIS
  141.   6.2 ITALY MARKET ANALYSIS BY APPLICATION
  142.   6.3 ITALY MARKET ANALYSIS BY END USE
  143.   6.4 ITALY MARKET ANALYSIS BY TYPE OF RADIOLIGAND
  144.   6.5 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE
  145.   6.6 ITALY MARKET ANALYSIS BY TARGET DISEASE
  146.   6.7 KEY BUYING CRITERIA OF HEALTHCARE
  147.   6.8 RESEARCH PROCESS OF MRFR
  148.   6.9 DRO ANALYSIS OF HEALTHCARE
  149.   6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  150.   6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  151.   6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
  152.   6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  153.   6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
  154.   6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
  155.   6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
  156.   6.17 HEALTHCARE, BY TYPE OF RADIOLIGAND, 2024 (% SHARE)
  157.   6.18 HEALTHCARE, BY TYPE OF RADIOLIGAND, 2024 TO 2035 (USD Billion)
  158.   6.19 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
  159.   6.20 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
  160.   6.21 HEALTHCARE, BY TARGET DISEASE, 2024 (% SHARE)
  161.   6.22 HEALTHCARE, BY TARGET DISEASE, 2024 TO 2035 (USD Billion)
  162.   6.23 BENCHMARKING OF MAJOR COMPETITORS
  163. 7 LIST OF TABLES
  164.   7.1 LIST OF ASSUMPTIONS
  165.     7.1.1
  166.   7.2 Italy MARKET SIZE ESTIMATES; FORECAST
  167.     7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  168.     7.2.2 BY END USE, 2026-2035 (USD Billion)
  169.     7.2.3 BY TYPE OF RADIOLIGAND, 2026-2035 (USD Billion)
  170.     7.2.4 BY ADMINISTRATION ROUTE, 2026-2035 (USD Billion)
  171.     7.2.5 BY TARGET DISEASE, 2026-2035 (USD Billion)
  172.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  173.     7.3.1
  174.   7.4 ACQUISITION/PARTNERSHIP
  175.     7.4.1

Italy Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2026-2035)

  • Oncology
  • Cardiology
  • Neurology
  • Endocrinology

Healthcare By End Use (USD Billion, 2026-2035)

  • Hospitals
  • Diagnostic Centers
  • Research Institutions
  • Pharmaceutical Companies

Healthcare By Type of Radioligand (USD Billion, 2026-2035)

  • Alpha Emitters
  • Beta Emitters
  • Auger Emitters
  • Radionuclide

Healthcare By Administration Route (USD Billion, 2026-2035)

  • Intravenous
  • Oral
  • Intratumoral

Healthcare By Target Disease (USD Billion, 2026-2035)

  • Prostate Cancer
  • Neuroendocrine Tumors
  • Lung Cancer
  • Thyroid Cancer

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓